Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Joaquín Martínez Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext )
jmartinezl@ext.cnio.es

Investigadores Científicos

Lucia Virginia Fernández
Miguel Gallardo
María Linares
Elena Maroto
Juan Manuel Rosa
María Velasco

Investigador Clínico I

Rosa María Ayala
Ana Jiménez

Becarios Post-doctorales

Noemí Álvarez
Almudena García
Larissa Anita Haertle
Ana Rodríguez
Alba Rodríguez
Antonio Valeri

Becarios Pre-Doctorales

Andrea Adrados
Pablo Blanco
Ángela Blanco
Eva Castellano
Lucía de la Mata
Roberto García
Alba Garrote
Adrián López
Sandra Lucía López
Eduardo Martínez
Miguel Ángel Marugal
Andrea Morillo Velarde
Andrea Ortí
Álvaro Otero
Juan Pérez

Técnicos de Laboratorio

Ana Isabel Aliaga
Raquel Ancos
Cristina Aragoneses
Andrés Arroyo
Laura Martín
Miguel Ángel Navarro
María Alejandra Ortiz

The Haematological Malignancies Clinical Research Unit focuses on the analysis and study of haematological diseases, including both neoplasms and dysplasia. To this end, we use basic, translational, and clinical approaches, employing novel transgenic in vitro and in vivo models as well as primary samples and clinical data from patients. Through the application of new technologies such as next-generation sequencing (NGS), nanopore sequencing, and artificial intelligence (AI), we seek to discover new diagnostic and prognostic biomarkers and hallmarks of resistance to current therapies, as well as to propose novel therapeutic targets and develop new preclinical trials.

In the Haematological Malignancies Clinical Research Unit at the CNIO, we investigate:

Mechanoreception: Its impact as a cancer driver on progression and treatment resistance.
Ageing and neoplasm: The transition between both and their impact on haematopoiesis.
Microbiota: Its role in B-cell malignancies and treatment opportunities.
Immunotherapy: NK-CARs, BiTEs, CAR-Ts, and immune checkpoint inhibitors.

Publicaciones recientes

Carreño-Tarragona G, Tiana M, Rouco R, Leivas A, Victorino J, García-Vicente R, Chase AJ, Maidana A, Tapper WJ, Ayala R, Cross NCP, Martínez-López J, Manzanares M. (2026). The JAK2 46/1 haplotype influences PD-L1 expression. Blood 145, 2196-2201. Publicación en otras instituciones.
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva SB, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC. (2025). International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol 43, 2739-2751. Publicación CNIO.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group (2025). Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma.. J Clin Oncol 43, 125-132. Publicación CNIO.
Lahuerta JJ, San-Miguel JF, Jiménez-Ubieto A, Alonso Fernández R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernandez M, Ríos-Tamayo R, Oriol A, Blanchard MJ, Carrillo-Cruz E, Martínez-Martínez R, Bargay J, Sureda A, de la Rubia J, Hernandez Garcia MT, Cabañas V, Casado Montero LF, Palomera Bernal L, Gonzalez-Montes Y, Martínez-López J, Rodriguez-Otero P, Krsnik I, Arguiñano JM, Gonzalez-Garcia ME, Ocio EM, de la Cruz J, Mateos MV, Rosiñol L, Bladé J. (2025). High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial. Blood 146, 1747-1758. Publicación CNIO.
Lasa M, Gonzalez C, Notarfranchi L, Zherniakova A, Alignani D, Burgos L, Calasanz MJ, Rodriguez-Otero P, Perez JJ, Gomez C, Gonzalez-Calle V, de Arriba F, Palomera Bernal L, Alvarez Rivas MA, Clavero Sanchez E, Ocio EM, Gonzalez-Rodriguez AP, Lakhwani S, Ibañez A, Oriol A, Sureda A, Rosiñol L, Siewert C, Orfao A, Lahuerta JJ, Bladé J, Mateos MV, San-Miguel JF, Cedena MT, Martinez-Lopez J, Puig N, Paiva B. (2025). Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment. Blood 146, 964-970. Publicación CNIO.
Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J (2025). Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.. Lancet Haematol 12, e588-e598. Publicación CNIO.
Monfort-Vengut A, Sanz-Gómez N, Ballesteros-Sánchez S, Ortigosa B, Cambón A, Ramos M, Lorenzo ÁM, Escribano-Cebrián M, Rosa-Rosa JM, Martínez-López J, Sánchez-Prieto R, Sotillo R, de Cárcer G. (2025). Osmotic stress influences microtubule drug response via WNK1 kinase signaling. Drug Resist Update 79, 101203. Publicación CNIO.
Rodríguez-García A, Ancos-Pintado R, García-Vicente R, Ortiz-Ruiz A, Arroyo A, Navarro MÁ, Morales ML, Guevara-Ramirez P, Justo P, López-Muñoz N, Sánchez-Pina J, Alonso R, Selma MV, Frutos-Lisón MD, García-Villalba R, Tomás-Barberán FA, Ayala R, Martínez-López J, Linares M. (2025). Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy. Microbiome 13, 56. Publicación CNIO.
Aguilar-Garrido P, Velasco-Estévez M, Navarro-Aguadero MÁ, Otero-Sobrino A, Ibañez-Navarro M, Marugal MÁ, Hernández-Sánchez M, Malaney P, Rodriguez A, Benitez O, Zhang X, Aitken MJ, Ortiz-Ruiz A, Megias D, Pérez-Martínez M, Mata G, Gomez J, Lafarga M, Dominguez O, Graña-Castro O, Caleiras E, Ximenez-Embun P, Isasa M, de Andrés PJ, Rodriguez-Perales S, Torres-Ruiz R, Revilla E, García-Martín RM, Azorín D, Zubicaray J, Sevilla J, Sirozh O, Lafarga V, Martinez-Lopez J, Post SM, Gallardo M. (2025). The tumor suppressor HNRNPK induces p53-dependent nucleolar stress to drive ribosomopathies. J Clin Invest 135, e183697. Publicación CNIO.
Mian H, Martin TG, Pond GR, Asoori S, Popat R, Kastritis E, Martinez-Lopez J, Abdallah N, Chhabra S, Parrondo R, Ailawadhi S, Dimopoulos MA, Yong K, Durie BG, Usmani SZ, Lin Y, Tan CR. (2025). Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia 39, 1252-1255. Publicación CNIO.
Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y. (2025). Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J 15, 53. Publicación CNIO.
Thorvaldsdottir B, Mansouri L, Sutton LA, Nadeu F, Meggendorfer M, Parker H, Brieghel C, Laidou S, Moia R, Rossi D, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfò L, Mattsson M, Davis Z, Baliakas P, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Hernández Rivas JM, Larráyoz MJ, Calasanz MJ, Smedby KE, Espinet B, Puiggros A, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. (2025). ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. Leukemia 39, 1650-1660. Publicación CNIO.
Izgutdina A, Rashid T, Temple WC, Aminov S, Patiño-Escobar B, Walunj S, Geng H, Takamatsu H, Gil-Alós D, Kang AS, Ramos E, Chen SY, Johnson H, Nix MA, Naik A, Li M, Yuan CM, Wang HW, Sahu S, Larson RC, Carpenter C, Salangsang F, Phojanakong P, Serrano JAC, Tariq I, Zakraoui O, Steri V, Valeri A, Martinez-Lopez J, Maus MV, Parekh S, Verma A, Shah NN, Wiita AP. (2025). Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies. J Immunother Cancer 13, e012013. Publicación CNIO.
Colmenares R, Alvarez N, Barragan E, Boluda B, Larrayoz MJ, Chillon MC, Soria-Saldise E, Bilbao C, Sanchez-Garcia J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Perez-Simon JA, Calbacho M, Alonso-Dominguez JM, Labrador J, Tormo M, Herrera-Puente P, Martin-Arriscado C, Arroyo-Barea A, Rapado I, Sargas C, Vazquez I, Calasanz MJ, Gomez-Casares T, Garcia-Sanz R, Rodriguez-Veiga R, Martinez-Lopez J, Ayala R, Montesinos P, Group P. (2025). Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry. Haematologica 110, 1263-1267. Publicación CNIO.
Falchi L, Hutchings M, Carlo-Stella C, Morschhauser F, Dickinson M, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody JD, Leppä S, Berthier A, Kallemeijn M, Relf J, Tchaleu FB, Lundberg L, Bachy E. (2025). Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma. Haematologica 110, 999-1004. Publicación CNIO.
Boluda B, Rodriguez-Veiga R, Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Soria-Saldise E, Bilbao C, Prados de la Torre E, Navarro I, Martinez-Cuadron D, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martínez-Sanchez P, Carrillo-Cruz E, Serrano J, Alonso-Domínguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, García-Pérez MJ, Morán J, Pérez-Santaolalla E, Alonso-Vence N, Oliva A, López JA, Barrios M, García-Fortes M, Olave MT, Labrador J, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-Garcia J, Mendizabal Y, Barragán E, Montesinos P; PETHEMA Group. (2025). Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study. Cancers 17, 584. Publicación CNIO.
Hermans SJF, Versluis J, van Werkhoven ED, van Norden Y, Janssen JJWM, Huls GA, Pabst T, Breems DA, Berkx E, Dinmohamed AG, Huijgens PC, Sträng E, Hernández Rivas JM, Sobas M, Ayala Diaz R, Martinez Lopez J, Metzeler KH, Haferlach T, Thiede C, Uyl-de Groot CA, Bullinger L, Löwenberg B, Ossenkoppele GJ, Pignatti F, Cornelissen JJ. (2025). Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients. Br J Haematol (in press). Publicación CNIO.
Nolan S, Vignali M, Klinger M, Dines JN, Kaplan IM, Svejnoha E, Craft T, Boland K, Pesesky MW, Gittelman RM, Snyder TM, Gooley CJ, Semprini S, Cerchione C, Nicolini F, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Sambri V, Martinelli G, Goldman JD, Heath JR, Notarangelo LD, Martinez-Lopez J, Howie B, Carlson JM, Robins HS. (2025). A large-scale database of T-cell receptor beta sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. Front Inmmunol 16, 1488851. Publicación CNIO.
Córdoba-Espejo L, Sánchez-Vega L, García-Ortiz A, Castellano E, Oliva R, Ortiz-Ruiz A, Gil-Alós D, Del Moral P, Fernández A, Sanjurjo D, López-García S, Perpiña U, Canals JM, Lee DA, Powell DJ Jr, Alonso R, Río P, Paciello ML, Valeri A, Leivas A, Martínez-López J. (2025). GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia. Cytotherapy 28, 101968. Publicación CNIO.
Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, DeVeaux M, Roccia T, Chokshi D, Seraphin M, Knorr K, Boyapati A, Hazra A, Rodriguez Lorenc K, Kroog GS, Bumma N, Richter J. (2025). Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clin. Lymphoma Myeloma Leuk. (in press). Publicación CNIO.
Velasco-Rodríguez D, Martínez-Alfonzo I, Velasco-Valdazo AE, Domingo-González A, Revilla N, Mahíllo-Fernández I, Askari E, Blanchard MJ, Vidal Laso R, Fernández-Cuezva L, Castro-Quismondo N, Prieto E, Serrano-López J, Rosado B, Naya D, Martín-Herrero S, Menéndez M, Yuste M, Sánchez-Prieto I, Jiménez-Martín A, Bueno MÁ, de la Plaza R, Martínez-López J, Calvo-Villas JM, López-Jiménez J, Llamas-Sillero P. (2025). Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy. J Thromb Thrombolys 58, 467-480. Publicación CNIO.
Encinas C, Lozano V, Hlavacek P, Llinares J, Toribio-Castelló S, Carcedo D, Asís-Montalt J, Martínez-López J. (2025). Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain. Oncol Ther 13, 381-395. Publicación CNIO.
Pello R, Iglesias MÁ, Vidal R, Mateos R, Outón M, Agulló C, Varo N, Blanco-Sánchez A, López-Muñoz N, García Á, Miras F, Iñiguez R, Gil-Alós D, Alonso R, López EA, Martínez-López J, Cedena MT. (2025). Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/ z Features and Concordance with Immunofixation Electrophoresis. Biomedicines 13, 2933. Publicación CNIO.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators; Investigators. (2024). European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol 42, 1875-1880. Publicación CNIO.
Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol 42, 2702-2712. Publicación CNIO.
Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). (2024). Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol 42, 3247-3256. Publicación CNIO.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. (2024). Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol (in press). Publicación CNIO.
Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S (2024). Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia 38, 1722-1730. Publicación CNIO.
Martinez-Lopez J, Lopez-Muñoz N, Chari A, Dorado S, Barrio S, Arora S, Kumar A, Chung A, Martin T, Wolf J. (2024). Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J 14, 131. Publicación CNIO.
Martinez-Verbo L, Veselinova Y, Llinàs-Arias P, García-Prieto CA, Noguera-Castells A, Pato ML, Bueno-Costa A, Campillo-Marcos I, Villanueva L, Oliver-Caldes A, Cardus O, Salsench SV, García-Ortiz A, Valeri A, Rojas EA, Barrena N, Gutiérrez NC, Prósper F, Agirre X, Fernández de Larrea C, Martínez-López J, Ferrer G, Esteller M. (2024). PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. Leukemia 38, 2722-2726. Publicación CNIO.
Oliver-Caldes A, Español-Rego M, Zabaleta A, González-Calle V, Navarro-Velázquez S, Inogés S, de Cerio AL, Cabañas V, López-Muñoz N, Rodríguez-Otero P, Reguera JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosiñol L, Cid J, Tovar N, Sáez-Peñataro J, López-Parra M, Olesti E, Guillén E, Varea S, Rodríguez-Lobato LG, Battram AM, González MS, Sánchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prósper F, Juan M, Martínez-López J, Moraleda JM, Mateos MV, Urbano-Ispizua Á, Paiva B, Pascal M, Fernández de Larrea C. (2024). Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res 30, 2085-2096. Publicación CNIO.
Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez-Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat JSP, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen SL, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten MJ, Mielke S. (2024). Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. Leukemia 38, 1985-1991. Publicación CNIO.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. (2024). The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. Blood Cancer J 14, 74. Publicación CNIO.
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. (2024). Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol 99, 586-595. Publicación CNIO.
Rodríguez-García A, Arroyo A, García-Vicente R, Morales ML, Gómez-Gordo R, Justo P, Cuéllar C, Sánchez-Pina J, López N, Alonso R, Puig N, Mateos MV, Ayala R, Gómez-Garre D, Martínez-López J, Linares M. (2024). Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma. Clin Cancer Res 30, 904-917. Publicación CNIO.
De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C, Ayala R, Bilbao-Sieyro C, Chillón MC, Larráyoz MJ, Soria E, Aparicio-Pérez C, Bergua JM, Bernal T, Gil C, Tormo M, Algarra L, Alonso-Domínguez JM, Rodriguez-Arbolí E, Martínez-Sanchez P, Oliva A, Colorado-Araujo AM, Rodríguez-Medina C, Vives S, Hermosín L, Martínez-López J, García-Sanz R, Pérez-Simón JA, Calasanz MJ, Gómez-Casares MT, Barragán E, Sánchez-García J J, Montesinos P. (2024). Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry. Haematologica 109, 2682-2687. Publicación CNIO.
Blanco-Sánchez A, Gil-Manso R, de Nicolás R, López-Muñoz N, Colmenares R, Mas R, Sánchez R, Rapado I, Martínez-López J, Díaz RA, Carreño-Tarragona G (2024). Real-world impact of deep targeted sequencing on erythrocytosis and thrombocytosis diagnosis: a reference centre experience. Cancers 16, 3149. Publicación CNIO.
Labrador J, Martínez-Cuadrón D, Boluda B, Serrano J, Gil C, Pérez-Simón JA, Bernal T, Bergua JM, Martínez-López J, Rodríguez-Medina C, Vidriales MB, García-Boyero R, Algarra L, Polo M, Sayas MJ, Tormo M, Alonso-Domínguez JM, Herrera P, Lavilla E, Ramos F, Amigo ML, Vives-Polo S, Rodríguez-Macías G, Mena-Durán A, Pérez-Encinas MM, Arce-Fernández O, Cuello R, Sánchez-García J, Gómez-Casares MT, Chillón MC, Calasanz MJ, Ayala R, Rodriguez-Veiga R, Barragán E, Montesinos P; PETHEMA Group. (2024). Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry. Cancer 130, 3436-3451. Publicación CNIO.
Martínez-López J, de la Cruz J, Gil-Manso R, Yuste VJ, Aspa-Cilleruelo JM, Escobar CE, López-Jiménez J, Duarte R, Yerovi CJ, Hernández-Rivas JÁ, Herráez R, Quiroz-Cervantes K, Bustelos-Rodriguez R, Benavente C, Martínez Barranco P, Bastos Oteiro M, Alegre A, Pérez-Oteyza J, Ruiz E, Marcheco-Pupo EA, Cedillo Á, de Soto Álvarez T, García Ramirez P, Alonso Trillo R, Herrera P, Bengochea Casado ML, Arroyo Barea A, Martin De Bustamante JM, Ortiz J, Calbacho Robles M, García-Suárez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). (2024). COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant. Cancers 16, 379. Publicación CNIO.
Álvarez N, Martín A, Dorado S, Colmenares R, Rufián L, Rodríguez M, Giménez A, Carneros L, Sanchez R, Carreño G, Rapado I, Heredia Y, Martínez-López J, Barrio S, Ayala R. (2024). Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges. Front Inmmunol 15, 1252258. Publicación CNIO.
Bermejo-Peláez D, Rueda Charro S, García Roa M, Trelles-Martínez R, Bobes-Fernández A, Hidalgo Soto M, García-Vicente R, Morales ML, Rodríguez-García A, Ortiz-Ruiz A, Blanco Sánchez A, Mousa Urbina A, Álamo E, Lin L, Dacal E, Cuadrado D, Postigo M, Vladimirov A, Garcia-Villena J, Santos A, Ledesma-Carbayo MJ, Ayala R, Martínez-López J, Linares M, Luengo-Oroz M. (2024). Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases. Microsc Microanal 30, 151-159. Publicación CNIO.
Caratis F, Opiełka M, Hausmann M, Velasco-Estevez M, Rojek B, de Vallière C, Seuwen K, Rogler G, Karaszewski B, Rutkowska A. (2024). The proton-sensing receptors TDAG8 and GPR4 are differentially expressed in human and mouse oligodendrocytes: Exploring their role in neuroinflammation and multiple sclerosis. PLoS One 19, e0283060. Publicación CNIO.
Dickinson M, Martinez-Lopez J, Jousseaume E, Yang H, Chai X, Xiang C, Wang T, Zhang J, Ramos R, Schuster SJ, Fowler N (2024). Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma 65, 323-332. Publicación CNIO.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. (2024). Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther 41, 1576-1593. Publicación CNIO.
Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, López-Martínez A, Altés A, Ruíz MÁ, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernández R, Bladé Creixenti J, Lahuerta JJ, San-Miguel J, Hernández MT. (2024). Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease. Ann Hematol (in press). Publicación CNIO.
Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Martínez-López J, Delforge M, Trancucci D, Pei L, Kobos R, Fastenau J, Gries KS, van de Donk NWCJ. (2024). Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Clin. Lymphoma Myeloma Leuk. 24, 194-202. Publicación CNIO.
Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodríguez C, Serrano J, Sayas MJ, Martínez-Sánchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Pérez-Simón JA, Herrera P, Barrios M, Noriega-Concepción V, Raposo-Puglia JA, Ayala R, Barragán E, Martínez-Cuadrón D, Amigo ML, López-Lorenzo JL, Lázaro-García A, Guimaraes JE, Colorado M, García-Boyero R, De Rueda-Ciller B, Foncillas-García M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group. (2024). Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?. Ann Hematol 103, 2845-2851. Publicación CNIO.
Algar S, Vázquez-Villa H, Aguilar-Garrido P, Navarro-Aguadero MÁ, Velasco-Estévez M, Sánchez-Merino A, Arribas-Álvarez I, Paradela A, Giner-Arroyo RL, Tamargo-Azpilicueta J, Díaz-Moreno I, Martínez-López J, Gallardo M, López-Rodríguez ML, Benhamú B. (2024). Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia. JACS Au 4, 1786-1800. Publicación CNIO.
De Ramón C, Rojas EA, Misiewicz-Krzeminska I, Cardona-Benavides IJ, Cuadrado M, Isidro I, Calasanz MJ, Fernandez M, García-Sanz R, Puig N, Cedena MT, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez NC; GEM/PETHEMA cooperative study group. (2024). Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients. Hemasphere 8, e70036. Publicación CNIO.
González-Calle V, Rodriguez-Otero P, Calasanz MJ, Guijarro M, Martínez-López J, Rosiñol L, Hernández MT, Teruel AI, Gironella M, Oriol A, de la Rubia J, González-Rodríguez AP, Bargay J, de Arriba F, Palomera L, González-Pérez MS, Sureda A, Ocio E, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Gutiérrez NC. (2024). High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. Hemasphere 8, e70031. Publicación CNIO.
Haertle L, Munawar U, Hernández HNC, Arroyo-Barea A, Heckel T, Cuenca I, Martin L, Höschle C, Müller N, Vogt C, Bischler T, Del Campo PL, Han S, Buenache N, Zhou X, Bassermann F, Waldschmidt J, Steinbrunn T, Rasche L, Stühmer T, Martinez-Lopez J, Martin Kortüm K, Barrio S. (2024). Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma. Hemasphere 8, e110. Publicación CNIO.
Ocio EM, Perrot A, Moreau P, Mateos MV, Bringhen S, Martínez-López J, Karlin L, Wang SY, Oprea C, Li Y, Kodas E, San-Miguel J. (2024). 30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. Hemasphere 8, e70041. Publicación CNIO.
Rodríguez-García A, Mennesson N, Hernandez-Ibarburu G, Morales ML, Garderet L, Bouchereau L, Allain-Maillet S, Piver E, Marbán I, Rubio D, Bigot-Corbel E, Martínez-López J, Linares M, Hermouet S. (2024). Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses. Haematologia 109, 272-282. Publicación CNIO. Open Access
Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. (2024). Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologia (in press). Publicación CNIO.
Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators. (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. New Engl J Med (in press). Publicación CNIO.
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Macé S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P. (2023). Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia 37, 1521-1529. Publicación CNIO. Open Access
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Dominguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez Casares MT, Sánchez-García J, Barragán E, Montesinos P; PETHEMA cooperative study group. (2023). Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 13, 77. Publicación CNIO. Open Access
Jiménez-Ubieto A, Poza M, Martin-Muñoz A, Ruiz-Heredia Y, Dorado S, Figaredo G, Rosa-Rosa JM, Rodriguez A, Barcena C, Navamuel LP, Carrillo J, Sanchez R, Rufian L, Juárez A, Rodriguez M, Wang C, de Toledo P, Grande C, Mollejo M, Casado LF, Calbacho M, Baumann T, Rapado I, Gallardo M, Sarandeses P, Ayala R, Martínez-López J, Barrio S. (2023). Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT. Leukemia (in press). Publicación CNIO.
Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoz MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R (2023). Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia 37, 339-347. Publicación CNIO.
Morales ML, García-Vicente R, Rodríguez-García A, Reyes-Palomares A, Vincelle-Nieto Á, Álvarez N, Ortiz-Ruiz A, Garrido-García V, Giménez A, Carreño-Tarragona G, Sánchez R, Ayala R, Martínez-López J, Linares M. (2023). Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia. Leukemia 37, 1649-1659. Publicación CNIO.
Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. (2023). Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J 13, 33. Publicación CNIO.
Nieto-Jiménez C, Sanvicente A, Díaz-Tejeiro C, Moreno V, Lopez de Sá A, Calvo E, Martínez-López J, Pérez-Segura P, Ocaña A. (2023). Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. Clin Transl Med 13, e1329. Publicación CNIO.
Cardona-Benavides IJ, Misiewicz-Krzeminska I, Rojas EA, De Ramón C, Sanz-Solas A, Isidro I, Quwaider D, López-Guerrero AM, Cuadrado M, Calasanz MJ, Rosiñol L, Martínez-López J, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez NC. (2023). Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling. Haematologica (in press). Publicación CNIO.
Lopez-Muñoz N, Hernández-Ibarburu G, Alonso R, Sanchez-Pina JM, Ayala R, Calbacho M, Cuellar C, Cedena MT, Jiménez-Ubieto A, Iñiguez R, Pedrera M, Cruz J, Meloni L, Pérez-Rey D, Serrano P, de la Cruz J, Martinez-Lopez J. (2023). Large-scale real-life analysis of survival and usage of therapies in multiple myeloma. J Hematol Oncol 16, 76. Publicación CNIO.
Ibáñez-Navarro M, Fernández A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero MÁ, Leivas A, Caracuel BR, Rodríguez-Antolín C, Ortiz A, Navarro-Zapata A, Mestre-Durán C, Izquierdo M, Balaguer-Pérez M, Ferreras C, Martínez-López J, Valés-Gómez M, Pérez-Martínez A, Fernández L. (2023). NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells. Front Inmmunol 14, . Publicación CNIO.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. (2023). Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. Br J Haematol 201, 1239-1244. Publicación CNIO.
Buenache N, Sánchez-delaCruz A, Cuenca I, Giménez A, Moreno L, Martínez-López J, Rosa-Rosa JM. (2023). Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq. Cancers 15, 2911. Publicación CNIO. Open Access
Carreño-Tarragona G, Álvarez-Larrán A, Hernández-Boluda JC, Ayala R, Cross NCP. (2023). Should we move to a genomic classification of neutrophilic myeloid neoplasms?. Blood Adv 7, 6705-6706. Publicación CNIO.
Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J (2023). Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma.. Cancers 15, 532. Publicación en otras instituciones.
Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J. (2023). Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase ( PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers 15, 532. Publicación CNIO.
Martínez-López J, De la Cruz J, Gil-Manso R, Alegre A, Ortiz J, Llamas P, Martínez Y, Hernández-Rivas JÁ, González-Gascón I, Benavente C, Estival Monteliu P, Jiménez-Yuste V, Canales M, Bastos M, Kwon M, Valenciano S, Callejas-Charavia M, López-Jiménez J, Herrera P, Duarte R, Núñez Martín-Buitrago L, Sanchez Godoy P, Jacome Yerovi C, Martínez-Barranco P, García Roa M, Escolano Escobar C, Matilla A, Rosado Sierra B, Aláez-Usón MC, Quiroz-Cervantes K, Martínez-Chamorro C, Pérez-Oteyza J, Martos-Martinez R, Herráez R, González-Santillana C, Del Campo JF, Alonso A, de la Fuente A, Pascual A, Bustelos-Rodriguez R, Sebrango A, Ruiz E, Marcheco-Pupo EA, Grande C, Cedillo Á, Lumbreras C, Arroyo Barea A, Casas-Rojo JM, Calbacho M, Diez-Martín JL, García-Suárez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). (2023). COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study. Cancers 15, 1497. Publicación CNIO.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. (2023). Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. Front Inmmunol 14, 1188818. Publicación CNIO. Open Access
Mussetti A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, Albo C, Bailen R, Barba P, Benzaquén A, Briones J, Caballero AC, Campos A, Español I, Ferra C, López SG, González Sierra PA, Guerra LM, Hernani R, Iacoboni G, Jiménez-Ubieto A, Kwon M, Corral LL, López-Godino O, Munoz MCM, Martínez-Cibrián N, Gómez JM, Pérez-Ortega L, Ortí G, Ortiz-Maldonado V, Pascual MJ, Perera M, Perez A, Reguera JL, Sanchez JM, Sanz J, Torrent A, Yáñez L, Varela R, Echechipia IC, Caballero D, Sureda A. (2023). Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplant 58, 673-679. Publicación CNIO.
Clavero E, Sanchez-Maldonado JM, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, García-Sanz R, Tomczak W, Vogel U, Jerez A, Zawirska D, Wątek M, Hofmann JN, Landi S, Spinelli JJ, Butrym A, Kumar A, Martínez-López J, Galimberti S, Sarasquete ME, Subocz E, Iskierka-Jażdżewska E, Giles GG, Rybicka-Ramos M, Kruszewski M, Abildgaard N, Verdejo FG, Sánchez Rovira P, da Silva Filho MI, Kadar K, Razny M, Cozen W, Pelosini M, Jurado M, Bhatti P, Dudzinski M, Druzd-Sitek A, Orciuolo E, Li Y, Norman AD, Zaucha JM, Reis RM, Markiewicz M, Rodríguez Sevilla JJ, Andersen V, Jamroziak K, Hemminki K, Berndt SI, Rajkumar V, Mazur G, Kumar SK, Ludovico P, Nagler A, Chanock SJ, Dumontet C, Machiela MJ, Varkonyi J, Camp NJ, Ziv E, Vangsted AJ, Brown EE, Campa D, Vachon CM, Netea MG, Canzian F, Försti A, Sainz J. (2023). Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24, 850. Publicación CNIO. Open Access
Otero-Sobrino Á, Blanco-Carlón P, Navarro-Aguadero MÁ, Gallardo M, Martínez-López J, Velasco-Estévez M. (2023). Mechanosensitive Ion Channels: Their Physiological Importance and Potential Key Role in Cancer. Int J Mol Med 24, 1371. Publicación CNIO.
Martínez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, Valluri S, Haefliger B, Gay F. (2023). Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol 19, 2103-2121. Publicación CNIO.
Rodríguez-García Y, Martínez-Moreno M, Alonso L, Sánchez-Vencells A, Arranz A, Dagà-Millán R, Sevilla-Movilla S, Valeri A, Martínez-López J, Teixidó J. (2023). Regulation of miRNA expression by α4β1 integrin-dependent multiple myeloma cell adhesion. Eur J Haematol 4, 631-638. Publicación CNIO.
Ayala R, Fernández RA, García-Gutiérrez V, Alvarez-Larrán A, Osorio S, Sánchez-Pina JM, Carreño-Tarragona G, Álvarez N, Gómez-Casares MT, Duran A, Gorrochategi J, Hernández-Boluda JC, Martínez-López J. (2023). Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study. Eur J Haematol 4, 401-409. Publicación CNIO. Open Access
Milara E, Alonso R, Masseing L, Seiffert AP, Gómez-Grande A, Gómez EJ, Martínez-López J, Sánchez-González P. (2023). Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma. Physiol Res 46, 903-913. Publicación CNIO. Open Access
Ocio EM, Bringhen S, Martinez-Lopez J, San-Miguel J, Oliva S, Rodriguez-Otero P, Le Roux N, Dong Y, Doroumian S, Macé S, Mateos MV. (2023). Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. Hemasphere 7, e829. Publicación CNIO. Open Access
Rodríguez-García A, Mennesson N, Hernandez-Ibarburu G, Morales ML, Garderet L, Bouchereau L, Allain-Maillet S, Piver E, Marbán I, Rubio D, Bigot-Corbel E, Martínez-López J, Linares M, Hermouet S. (2023). Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses. Haematologia (in press). Publicación CNIO.
Stölzel F, Fordham SE, Nandana D, Lin WY, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura EN, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Röllig C, Wagenführ L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhäuser M, Allan JM. (2023). Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia. JCI Insight 8, e150368. Publicación CNIO.
Zhou X, Han S, Cebulla N, Haertle L, Steinhardt MJ, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Mersi J, Munawar U, Schindehütte M, Blum R, Reinhold AK, Scherf-Clavel O, Rittner HL, Pham M, Rasche L, Einsele H, Sommer C, Kortüm KM. (2023). Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1. Biomark Res 16, 52. Publicación CNIO. Open Access
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. New Engl J Med 386, 629-639. Publicación CNIO.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28, 325-332. Publicación CNIO.
Garcés JJ, Cedena MT, Puig N, Burgos L, Perez JJ, Cordon L, Flores-Montero J, Sanoja-Flores L, Calasanz MJ, Ortiol A, Blanchard MJ, Rios R, Martin J, Martínez-Martinez R, Bargay J, Sureda A, de la Rubia J, Hernandez MT, Rodriguez-Otero P, de la Cruz J, Orfao A, Mateos MV, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, San-Miguel JF, Paiva B (2022). Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin Oncol 40, 3151-3161. Publicación CNIO.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Alonso Fernandez R, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. (2022). Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res (in press). Publicación CNIO.
Termini R, Zihala D, Terpos E, Pérez-Montaña A, Jelinek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodríguez S, Moreno C, Perez C, Maia C, Martin-Sanchez E, Guerrero C, Botta C, Garcés JJ, Lopez A, Tamariz-Amador LE, Prósper F, Bargay J, Cabezudo ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldes C, Matos Silva H, Gomez C, De Arriba F, Ludwig H, Garcia-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, De la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B (2022). Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res (in press). Publicación CNIO.
Mosquera Orgueira A, González Pérez MS, Diaz Arias J, Rosiñol L, Oriol A, Teruel AI, Martinez Lopez J, Palomera L, Granell M, Blanchard MJ, de la Rubia J, López de la Guia A, Rios R, Sureda A, Hernandez MT, Bengoechea E, Calasanz MJ, Gutierrez N, Martin ML, Blade J, Lahuerta JJ, San Miguel J, Mateos MV; PETHEMA/GEM Cooperative Group. (2022). Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer J 12, 76. Publicación CNIO.
Sanz A, Ayala R, Hernández G, Lopez N, Gil-Alos D, Gil R, Colmenares R, Carreño-Tarragona G, Sánchez-Pina J, Alonso RA, García-Barrio N, Pérez-Rey D, Meloni L, Calbacho M, Cruz-Rojo J, Pedrera-Jiménez M, Serrano-Balazote P, de la Cruz J, Martínez-López J (2022). Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network. Blood Cancer J 12, 94. Publicación CNIO.
Rojas EA, Corchete LA, De Ramón C, Krzeminski P, Quwaider D, García-Sanz R, Martínez-López J, Oriol A, Rosiñol L, Bladé J, Lahuerta JJ, San Miguel JF, González M, Mateos MV, Bourdon JC, Misiewicz-Krzeminska I, Gutiérrez NC. (2022). Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. Am J Hematol 97, 700-710. Publicación CNIO.
Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, Schäfer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause SW, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Miñana L, Hänel M, Acuña-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago-Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Levis M, Montesinos P, Röllig C, Schlenk RF (2022). Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. Haematologica (in press). Publicación CNIO.
Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczynska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudzinski M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Razny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Várkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D (2022). A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer (in press). Publicación CNIO.
Rodríguez-García A, Linares M, Morales ML, Allain-Maillet S, Mennesson N, Sanchez R, Alonso R, Leivas A, Pérez-Rivilla A, Bigot-Corbel E, Hermouet S, Martínez-López J (2022). Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma. Front Inmmunol 12, 797209. Publicación CNIO.
Valeri A, García-Ortiz A, Castellano E, Córdoba L, Maroto-Martín E, Encinas J, Leivas A, Río P, Martínez-López J. (2022). Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Inmmunol 13, 953849. Publicación CNIO.
Ancos-Pintado R, Bragado-García I, Morales ML, García-Vicente R, Arroyo-Barea A, Rodríguez-García A, Martínez-López J, Linares M, Hernández-Sánchez M. (2022). High-Throughput CRISPR Screening in Hematological Neoplasms. Cancers 14, 3612. Publicación CNIO.
Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao C, Sánchez-García J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Pérez-Simón JA, Calbacho M, Alonso-Domínguez JM, Labrador J, Tormo M, Amigo ML, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz MJ, Gomez-Casares T, García-Sanz R, Sanz MA, Martínez-López J, Montesinos P. (2022). Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. Cancers 14, 5799. Publicación CNIO. Open Access
Carreño-Tarragona G, Alvarez-Larran A, Harrison CN, Martínez-Ávila JC, Hernandez-Boluda JC, Ferrer-Marin F, Radia DH, Mora Casterá E, Francis S, González-Martínez T, Goddard K, Perez-Encinas M, Narayanan S, Raya JM, Singh V, Toth P, Gutiérrez X, Amat Martinez P, McIlwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares CL, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufian L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NC. (2022). CNL and aCML should be considered as single entity based on molecular profiles and outcomes. Blood Adv (in press). Publicación CNIO. Open Access
Colmenares R, Álvarez N, Barrio S, Martínez-López J, Ayala R (2022). The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies. Cancers 14, 1310. Publicación CNIO.
Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M, Martínez-Sánchez P, Rodríguez-Arbolí E, García-Boyero R, Rodríguez-Medina C, Martínez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Espadana A, Sayas MJ, Algarra L, Vidriales MB, Vasconcelos G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Chillón MC, Rodríguez-Gutiérrez JI, Calasanz MJ, Labrador J, López JA, Boluda B, Rodríguez-Veiga R, Martínez-López J, Barragán E, Sanz MA, Montesinos P, On Behalf Of The Pethema Group. (2022). Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. Cancers 14, 2817. Publicación CNIO.
Puig N, Sanfeliciano TC, Agullo Roca C, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios-Tamayo R, Martín Sánchez J, Iñigo MB, Sureda A, Hernandez Garcia MT, de la Rubia J, Gonzalez-Calle V, Krsnik I, Cabañas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Mateos MV (2022). Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv 6, 3234-3239. Publicación CNIO.
Rosa-Rosa JM, Cuenca I, Medina A, Vázquez I, Sánchez-delaCruz A, Buenache N, Sánchez R, Jiménez C, Rosiñol L, Gutiérrez NC, Ruiz-Heredia Y, Barrio S, Oriol A, Martin-Ramos ML, Blanchard MJ, Ayala R, Ríos-Tamayo R, Sureda A, Hernández MT, de la Rubia J, Alkorta-Aranburu G, Agirre X, Bladé J, Mateos MV, Lahuerta JJ, San-Miguel JF, Calasanz MJ, Garcia-Sanz R, Martínez-Lopez J. (2022). NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial. Cancers 14, 5169. Publicación CNIO.
Milara E, Gómez-Grande A, Tomás-Soler S, Seiffert AP, Alonso R, Gómez EJ, Martínez-López J, Sánchez-González P. (2022). Bone marrow segmentation and radiomics analysis of [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma. Comput Meth Prog Bio (in press). Publicación CNIO.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J (2022). Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Sci Rep 12, 13057. Publicación CNIO.
Fernández A, Pérez-Martínez A, Escudero A, Mirones I, González B, de Paz R, Matamala N, Clares L, Navarro A, Galán V, Martínez-Romera I, Martínez-López J, Leivas A, Valés-Gómez M, Ferreras C, Fernández L (2022). Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits. Leuk Lymphoma 63, 1970-1974. Publicación CNIO.
Hernández-Boluda JC, Martínez-Cuadrón D, Pereira A, Rodríguez-Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martínez-López J, Bergua J, Algarra L, Bernal T, López-Lorenzo JL, Colorado M, López A, Tormo M, Sayas MJ, Trigo F, López-Pavía M, Pérez-Simón JA, Lavilla-Rubira E, Rodríguez-Medina C, Rodríguez-Gutiérrez JI, Sanz-Caballer MA, Montesinos P; PETHEMA group. (2022). Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. Leuk Res 115, 106821. Publicación CNIO.
San-Juan R, Fernández-Ruiz M, López-Medrano F, Carretero O, Lalueza A, Maestro de la Calle G, Pérez-Jacoiste Asín MA, Bueno H, Caro-Teller JM, Catalán M, de la Calle C, García-García R, Gómez C, Laguna-Goya R, Lizasoáin M, Martínez-López J, Origüen J, Sevillano Á, Gutiérrez E, de Miguel B, Aguilar F, Parra P, Ripoll M, Ruiz-Merlo T, Trujillo H, Pablos JL, Paz-Artal E, Lumbreras C, Aguado JM; H12O Immunomodulation Therapy for COVID-19 Group, the Spanish Network for Research in Infectious Diseases (REIPI). (2022). Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. Int J Infect Dis 117, 56-64. Publicación CNIO.
Zozaya N, Villaseca J, Abdalla F, Calleja MA, Díez-Martín JL, Estévez J, García-Sanz R, Martínez-López J, Sierra J, Vera R, Hidalgo-Vega A. (2022). A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clin Transl Oncol 8, 1-13. Publicación CNIO.
García-Ríos E, Leivas A, Mancebo FJ, Sánchez-Vega L, Lanzarot D, Aguado JM, Martínez-López J, Paciello ML, Pérez-Romero P. (2022). Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. Biomedicines 10, 630. Publicación CNIO.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ (2021). Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial.. J Clin Oncol 39, 1959-1970. Publicación CNIO.
Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Perez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. (2021). Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood 138, 1583-1589. Publicación CNIO.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fernández RA, Bittrich M, Ruiz-Heredia Y, Da Viá M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero JI, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM (2021). Cereblon Enhancer Methylation and IMiD resistance in multiple myeloma. Blood 138, 721-726. Publicación CNIO.
Jiménez Ubieto A, Paiva B, Puig N, Cedena MT, Martínez-Lopez J, Oriol A, Blanchard MJ, Ríos Tamayo R, Martín Sánchez J, Martinez R, Sureda A, Hernandez Garcia MT, de la Rubia J, Krsnik I, Cabañas V, Palomera L, Sanchez-Pina J, Bargay J, Mateos MV, Rosiñol Dachs L, Bladé J, San-Miguel JFF, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Español de Tratamientos en Hematología) Cooperative Study Group (2021). Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. Blood 138, 1901-1905. Publicación CNIO.
Carreño-Tarragona G, Varghese LN, Sebastián E, Gálvez E, Marín-Sánchez A, López-Muñoz N, Nam-Cha S, Martínez-López J, Constantinescu SN, Sevilla J, Ayala R. (2021). A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. Leukemia 35, 3295-3298. Publicación CNIO.
Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, Onecha E, Lecumberri R, Prosper F, Ocio EM, González ME, García de Coca A, De La Rubia J, Gironella M, Palomera L, Oriol A, Casanova M, Cabañas V, Taboada F, Pérez-Montaña A, De Arriba F, Puig N, Carreño-Tarragona G, Barrio S, Enrique de la Puerta J, Ramirez-Payer A, Krsnik I, Bargay JJ, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B, Lopez JM (2021). Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis.. Leukemia 35, 245-249. Publicación CNIO.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J (2021). NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J 11, 146. Publicación CNIO.
Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz CP, Metafuni E, Martinez-Lopez J, Dignan FL, Ribera JM, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten MJ, Mielke S. (2021). Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia 35, 3585-3588. Publicación CNIO.
Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. (2021). Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol 14, 126. Publicación CNIO.
Macauda A, Piredda C, Clay-Gilmour AI, Sainz J, Buda G, Markiewicz M, Barington T, Ziv E, Hildebrandt MAT, Belachew AA, Varkonyi J, Prejzner W, Druzd-Sitek A, Spinelli J, Andersen NF, Hofmann JN, Dudzinski M, Martinez-Lopez J, Iskierka-Jazdzewska E, Milne RL, Mazur G, Giles GG, Ebbesen LH, Rymko M, Jamroziak K, Subocz E, Reis RM, Garcia-Sanz R, Suska A, Haastrup EK, Zawirska D, Grzasko N, Vangsted AJ, Dumontet C, Kruszewski M, Dutka M, Camp NJ, Waller RG, Tomczak W, Pelosini M, Razny M, Marques H, Abildgaard N, Watek M, Jurczyszyn A, Brown EE, Berndt S, Butrym A, Vachon CM, Norman AD, Slager SL, Gemignani F, Canzian F, Campa D. (2021). Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. Int J Cancer 149, 327-336. Publicación CNIO.
Malaney P, Velasco-Estevez M, Aguilar-Garrido P, Aitken MJL, Chan LE, Zhang X, Post SM, Gallardo M (2021). The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies. Front Inmmunol 12, 634584. Publicación CNIO.
Ocio EM, Motlló C, Rodríguez-Otero P, Martínez-López J, Cejalvo MJ, Martín-Sánchez J, Bladé J, García-Malo MD, Dourdil MV, García-Mateo A, de Arriba F, García-Sanz R, de la Rubia J, Oriol A, Lahuerta JJ, San-Miguel JF, Mateos MV. (2021). Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. Br J Haematol 192, 522-530. Publicación CNIO.
Fernández A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodríguez-Antolín C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martínez J, Fernández L, Pérez-Martínez A (2021). Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy.. Cancers 13, 577. Publicación CNIO.
García-Ortiz A, Rodríguez-García Y, Encinas J, Maroto-Martín E, Castellano E, Teixidó J, Martínez-López J (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers 13, 217. Publicación CNIO.
Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M. (2021). Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers 13, 3189. Publicación CNIO.
Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Montesinos P. (2021). Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Adv 5, 760-770. Publicación CNIO.
Castaño-Bonilla T, Alonso-Dominguez JM, Barragán E, Rodríguez-Veiga R, Sargas C, Gil C, Chillón C, Vidriales MB, García R, Martínez-López J, Ayala R, Larrayoz MJ, Anguita E, Cuello R, Cantalapiedra A, Carrillo E, Soria-Saldise E, Labrador J, Recio I, Algarra L, Rodríguez-Medina C, Bilbao-Syeiro C, López-López JA, Serrano J, De Cabo E, Sayas MJ, Olave MT, Sánchez-García J, Mateos M, Blas C, López-Lorenzo JL, Lainez-Gonzalez D, Serrano J, Martínez-Cuadrón D, Sanz MA, Montesinos P. (2021). Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Sci Rep 11, 20745. Publicación CNIO.
Stefania Infante M, Fernández-Cruz A, Núñez L, Carpio C, Jiménez-Ubieto A, López-Jiménez J, Vásquez L, Del Campo R, Romero S, Alonso C, Morillo D, Prat M, Luis Plana J, Villafuerte P, Bastidas G, Bocanegra A, Serna Á, De Nicolás R, Marquet J, Mas-Ochoa C, Cordoba R, García-Suárez J, Comai A, Martín X, Bastos-Oreiro M, Seri C, Navarro-Matilla B, López-Guillermo A, Martínez-López J, Ángel Hernández-Rivas J, Ruiz-Camps I, Grande C; Grupo Español de Linfomas y Trasplante Autólogo de Medula Ósea (GELTAMO). (2021). Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Med 10, 7629-7640. Publicación CNIO.
Álvarez N, Rodríguez-García A, Morales ML, Gutiérrez M, Montero M, Poza M, López N, Carreño G, Sánchez R, Cedena T, Rapado I, Martínez-López J, Ayala R. (2021). Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. Leuk Res 108, 106613. Publicación CNIO.
de la Calle C, López-Medrano F, Pablos JL, Lora-Tamayo J, Maestro-de la Calle G, Sánchez-Fernández M, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Caro-Teller JM, García-García R, Catalán M, Martínez-López J, Sevillano Á, Origüen J, Ripoll M, San Juan R, Lalueza A, de Miguel B, Carretero O, Aguilar F, Gómez C, Paz-Artal E, Bueno H, Lumbreras C, Aguado JM. (2021). Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. Int J Infect Dis 105, 319-325. Publicación CNIO.
Gómez García LM, Escudero A, Mestre C, Fuster Soler JL, Martínez AP, Vagace Valero JM, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, De Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. (2021). Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. Clin. Lymphoma Myeloma Leuk. 21, 328-337. Publicación CNIO.
Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, Vives S, Bergua JM, Torrent A, Suárez-Varela S, Boluda B, Martínez-López J, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Martín-Herreros B, Serrano A, Sempere A, Barragán E, Sargas C, Sanz M, Martínez-Cuadrón D, Montesinos P; PETHEMA group. (2021). A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Ann Hematol 100, 1497-1508. Publicación CNIO.
Martínez-López J, Mustjoki S, Porkka K, Klisovic RB, Wolf D, Busque L, Hernández-Boluda JC, Swanink R, Martin Regueira P, Lipton JH. (2021). The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Leuk Lymphoma 62, 2040-2043. Publicación CNIO.
Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D, Gil Alos D, Ayala R, Martinez-Lopez J. (2021). Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol 43, 0152-0155. Publicación CNIO.
Carreras P, González I, Gallardo M, Ortiz-Ruiz A, Morales ML, Encinas J, Martínez-López J. (2021). Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. Micromachines 12, 90. Publicación CNIO.